Status:
COMPLETED
Study of the Model to Predict 3-month Mortality Risk of Acute-on-chronic Hepatitis B Liver Failure
Lead Sponsor:
Wenzhou Medical University
Conditions:
Acute-on-chronic Hepatitis B Liver Failure
Eligibility:
All Genders
19-87 years
Brief Summary
This study was to predict 3-month mortality risk of acute-on-chronic hepatitis B liver failure (ACHBLF) on an individual patient level using artificial neural network (ANN) system. The area under the ...
Detailed Description
Hepatitis B virus (HBV) is a major human pathogen which causes high morbidity and mortality worldwide. HBV is one of the leading causes for rapid deterioration of liver function, which is a serious co...
Eligibility Criteria
Inclusion
- Acute hepatic insult manifesting as jaundice and coagulopathy
- Complicated within 4 weeks by ascites
- And/or encephalopathy in a patient with chronic HBV infection
Exclusion
- Patients with evidence of non-B hepatitis virus
- alcohol abuse leads to liver failure
- autoimmune leads to liver failure
- oxic or other causes that might lead to liver failure
- past or current hepatocellular carcinoma
- liver transplantation
- serious diseases in other organ systems
Key Trial Info
Start Date :
April 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
583 Patients enrolled
Trial Details
Trial ID
NCT01826760
Start Date
April 1 2010
End Date
June 1 2010
Last Update
April 8 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wenzhou Medical College
Wenzhou, Zhejiang, China, 325000